Company news

Neurizon Therapeutics Limited news in 2019

Neurizon Therapeutics Limited's news releases, calls and decks from 2019, newest first.

View company

Expanded Site Recruitment for Phase II MPL Dog Cancer Trial

December 11, 2019

Presentation - Pitt Street Research Life Sciences Conference

November 27, 2019

Progress in Recruitment for Phase II Trial in Dogs

November 3, 2019

AGM Presentation

October 25, 2019

Epichem new CEO and Board additions

October 14, 2019

Appendix 3B & s708 Notice

October 10, 2019

PharmAust Receives Pre-Approval for R&D Tax Rebates

October 6, 2019

Epichem Export Business Receives Important WA State Awards

October 3, 2019

PharmAust Raises $2.4m in Placement

October 2, 2019

Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial

September 9, 2019

Phase II Dog Cancer Trial Commences

September 8, 2019

Investor Roadshow Presentation - September 2019

September 8, 2019

Preliminary Final Report

August 30, 2019

Receipt of GMP Grade Tablets for Phase II Trials

August 25, 2019

Response to ASX Price and Volume Query

July 23, 2019

PharmAust receives ethics approval to begin Phase II Trial

July 14, 2019

Epichem Final Loan Repayment Milestone for New Laboratory

July 1, 2019

PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial

June 3, 2019

Receipt of 25kg of GMP-Grade Monepantel from Elanco

May 8, 2019

Phase I Canine Repeat Dose MPL Demonstrates High Performance

May 5, 2019

PharmAust Receives $672,250 R&D Tax Incentive Refund

April 29, 2019

Shortfall Placement Oversubscribed

April 11, 2019

Phase I Monepantel Tablets Demonstrate High Safety

March 27, 2019

PharmAust Raises $1.3m in Rights Issue

March 21, 2019

MPL Tablets Demonstrate Positive Performance in Phase 1

March 13, 2019

PharmAust Rights Issue Reaches Minimum Subscription

March 12, 2019

Appendix 4D & Financial Report

February 28, 2019

Offer Document - Rights Issue

February 25, 2019

Phase I Dog Trial with New Monepantel Tablets Commences

February 19, 2019

Non-Renounceable Rights Offer

February 17, 2019

PAA Completes Successful Taste Mask Testing of New Tablet

February 10, 2019

PharmAust Signs Agreement for US Phase I Trials in Dogs

February 6, 2019

PharmAust Completes Scaled Manufacture of Monepantel Tablets

February 6, 2019

PharmAust Appendix 4C and Shareholders Update

January 31, 2019

PharmAust and Elanco Execute Data Sharing Agreement

January 28, 2019

Optimisation of Monepantel Uptake

January 20, 2019

Monepantel Principal Metabolite Shows Anti-Cancer Activity

January 13, 2019

Decks in 2019